June 9, 2022 12:20 PM EDTUpdated 03:46 PM
Bioregnum

#BIO22: Com­ing to­geth­er at a crit­i­cal time, End­points News looks at the key met­rics on bio­phar­ma in a tur­bu­lent time

Back at the be­gin­ning of the year dur­ing JP Mor­gan, I came up with my usu­al set of pro­jec­tions for the year ahead and def­i­nite­ly …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times